Loading...
Loading...
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR. Spoken Alpha tracks JHPCY's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks JHPCY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for JHPCY.
curl https://api.spokenalpha.com/v1/companies/JHPCY| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.81 | $4.49 | +29.3% | -1.8% | -4.6% |
| Q4 FY2026 | $5.89 | $4.36 | +35.1% | +1.3% | +1.6% |
| Q3 FY2026 | $5.67 | $4.43 | +27.9% | +3.6% | +5.7% |
| Q2 FY2026 | $6.03 | $4.54 | +32.9% | -1.7% | +0.9% |
| Q1 FY2025 | $5.94 | $4.49 | +32.3% | -3.4% | -5.1% |
| Q4 FY2025 | $6.08 | $4.42 | +37.6% | -6.3% | -5.7% |
| Q3 FY2025 | $6.17 | $4.48 | +37.8% | -2.4% | -4.8% |
| Q2 FY2025 | $5.75 | $4.57 | +25.9% | +4.7% | +2.1% |
| Q1 FY2024 | $6.02 | $4.62 | +30.3% | -1.2% | -3.0% |
| Q4 FY2024 | $6.18 | $4.49 | +37.6% | 0.0% | +2.5% |